Business Context and Reporting Period
This Form 6-K filing by MediWound Ltd. covers the month of August 2023, with a specific report date of August 15, 2023. The document serves as a Report of Foreign Private Issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance update and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of a new Board member. On August 15, 2023, the Board appointed Mr. Shmuel (Milky) Rubinstein to replace Mr. Assaf Segal, who stepped down. The filing explicitly states that Mr. Segal's resignation was not the result of any disagreement with the Company, its management, or the Board.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document focuses solely on the board composition change and incorporates the report by reference into various Registration Statements on Forms S-8 and F-3.
Investor Verification Checklist
- Verify the professional background and potential conflicts of interest for the newly appointed director, Mr. Shmuel Rubinstein.
- Confirm the effective date of Mr. Assaf Segal's departure from the Board.
- Review the referenced Registration Statements (Forms S-8 and F-3) for any material updates regarding equity plans or capital raising that may be affected by the board change.